Coronary Sinus Reducer an Option for Intractable Angina? : vimarsana.com

A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.

Related Keywords

London , City Of , United Kingdom , Cincinnati , Ohio , United States , North Carolina , Canada , Duke University , Canadian , Michaelj Foley , Jennifera Rymer , Timothyd Henry , Rashak Al Lamee , , American College Of Cardiology , Research At Christ Hospital , Imperial College Healthcare , Lindner Center , Foley , Canadian Cardiovascular Society , Imperial College London , Duke University School Of Medicine , European Society Of Cardiology , Imperial College Healthcare Trust , American College , Neovasc Reducer , Shockwave Medical , Seattle Angina Questionnaire , Macnew Heart Disease , One Measure , Duke University School , Christ Hospital , Angina , Ngina Pectoris , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Oronary Artery Disease , Sinus , Quality Of Life , Ol , Ealth Related Quality Of Life , Rqol , Otolaryngology , Nt Specialty , Ead And Neck Surgery Ent Speciality , Antianginals , Ntianginal Agents , Blood , Refractory ,